常年亏损，集采拖累，_老虎社区_美港股上老虎

TabFnlk
2021-09-03

常年亏损，集采拖累，疫情蔓延，种种迹象表明业绩将在四五年内长期下降，目标价20.2比较合适。

麦格理：维持微创医疗“跑输大市”评级目标价降20.2%至42.57港元

麦格理发布研究报告称，维持微创医疗(00853)“跑输大市”评级，目标价由53.38港元下调至42.57港元，将2021-23年的每股盈利预测分别下调11%/50%/260%。报告中称，虽然公司上半年手术量有所恢 ...

麦格理：维持微创医疗“跑输大市”评级目标价降20.2%至42.57港元

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":815121724,"tweetId":"815121724","gmtCreate":1630658106068,"gmtModify":1630658106068,"author":{"id":3544606489804355,"idStr":"3544606489804355","authorId":3544606489804355,"authorIdStr":"3544606489804355","name":"TabFnlk","avatar":"https://static.tigerbbs.com/85ffd07624617a0ec8c253836967ae8b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>常年亏损，集采拖累，疫情蔓延，种种迹象表明业绩将在四五年内长期下降，目标价20.2比较合适。</p></body></html>","htmlText":"<html><head></head><body><p>常年亏损，集采拖累，疫情蔓延，种种迹象表明业绩将在四五年内长期下降，目标价20.2比较合适。</p></body></html>","text":"常年亏损，集采拖累，疫情蔓延，种种迹象表明业绩将在四五年内长期下降，目标价20.2比较合适。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/815121724","repostId":2164873530,"repostType":2,"repost":{"id":"2164873530","pubTimestamp":1630653757,"share":"https://www.laohu8.com/m/news/2164873530?lang=&edition=full","pubTime":"2021-09-03 15:22","market":"sh","language":"zh","title":"麦格理：维持微创医疗“跑输大市”评级 目标价降20.2%至42.57港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2164873530","media":"智通财经","summary":"麦格理发布研究报告称，维持微创医疗(00853)“跑输大市”评级，目标价由53.38港元下调至42.57港元，将2021-23年的每股盈利预测分别下调11%/50%/260%。报告中称，虽然公司上半年手术量有所恢 ...","content":"<html><body><div>\n<p>　　麦格理发布研究报告称，维持<a href=\"https://laohu8.com/S/00853\">微创医疗</a>(00853)“跑输大市”评级，目标价由53.38港元下调至42.57港元，将2021-23年的每股盈利预测分别下调11%/50%/260%。</p><p>　　报告中称，虽然公司上半年手术量有所恢复，但鉴于Delta变种病毒对海外业务的影响和即将到来的骨科集中采购(GPO)存不确定性，管理层的全年指引变得更加保守，仅预计销售增长将达到之前20%至27%的指引下限。</p><p>　　该行表示，骨科业务增长指引从25%至30%下调至15%至20%，以反映预期从第三季度开始GPO的潜在分销商去库存。该行对中国骨科业务看法仍然较负面，并预计未来仨年的年复合增长率仅为11%。</p>\n<p><strong>关注<a href=\"https://laohu8.com/S/300033\">同花顺</a>财经（ths518），获取更多机会</strong></p>\n<span></span>\n<div><span>责任编辑：lg</span></div>\n</div></body></html>","source":"tonghuashun","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>麦格理：维持微创医疗“跑输大市”评级 目标价降20.2%至42.57港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n麦格理：维持微创医疗“跑输大市”评级 目标价降20.2%至42.57港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 15:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://stock.10jqka.com.cn/hks/20210903/c632432586.shtml><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>麦格理发布研究报告称，维持微创医疗(00853)“跑输大市”评级，目标价由53.38港元下调至42.57港元，将2021-23年的每股盈利预测分别下调11%/50%/260%。　　报告中称，虽然公司上半年手术量有所恢复，但鉴于Delta变种病毒对海外业务的影响和即将到来的骨科集中采购(GPO)存不确定性，管理层的全年指引变得更加保守，仅预计销售增长将达到之前20%至27%的指引下限。　　该行表示，...</p>\n\n<a href=\"http://stock.10jqka.com.cn/hks/20210903/c632432586.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{"00853":"微创医疗"},"source_url":"http://stock.10jqka.com.cn/hks/20210903/c632432586.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","article_id":"2164873530","content_text":"麦格理发布研究报告称，维持微创医疗(00853)“跑输大市”评级，目标价由53.38港元下调至42.57港元，将2021-23年的每股盈利预测分别下调11%/50%/260%。　　报告中称，虽然公司上半年手术量有所恢复，但鉴于Delta变种病毒对海外业务的影响和即将到来的骨科集中采购(GPO)存不确定性，管理层的全年指引变得更加保守，仅预计销售增长将达到之前20%至27%的指引下限。　　该行表示，骨科业务增长指引从25%至30%下调至15%至20%，以反映预期从第三季度开始GPO的潜在分销商去库存。该行对中国骨科业务看法仍然较负面，并预计未来仨年的年复合增长率仅为11%。\n关注同花顺财经（ths518），获取更多机会\n\n责任编辑：lg","news_type":1},"isVote":1,"tweetType":1,"viewCount":1868,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":83,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

麦格理：维持微创医疗“跑输大市”评级 目标价降20.2%至42.57港元

评论

热议股票

麦格理：维持微创医疗“跑输大市”评级目标价降20.2%至42.57港元